早期银屑病关节炎炎症 Tight Control 的成本效果:多中心随机对照试验的经济学分析
该研究基于英国多中心开放标签随机对照试验,从医疗保健部门视角评估早期银屑病关节炎(PsA)Tight Control(TC)策略相比标准治疗的成本效果,时间跨度48周。TC组平均成本更高(£4,198 vs £2,000),QALY也更高(0.602 vs 0.561),增量成本效果比(ICER)为£53,948/QALY。在£20,000阈值下TC具有成本效果的概率为0.07;分层分析显示对疾病严重程度较高的患者、在控制部分成本后ICER为£24,639。结论认为TC是有效干预,但在多数分析中不具有成本效果。
要点
- 早期PsA的TC策略48周ICER为£53,948/QALY,在£20,000阈值下成本效果概率仅0.07。
- TC组平均成本£4,198、QALY 0.602,均高于标准治疗组的£2,000和0.561。
- 对疾病严重程度较高的患者、在控制部分成本后ICER可降至£24,639。
核心结论
- Tight Control策略治疗PsA是治疗路径中的有效干预,但本研究在多数分析中未发现其具有成本效果。
- 降低药物价格、针对多关节炎患者或减少风湿科就诊频率,可能改善未来研究的性价比指标。
研究设计与样本
- 成本效果分析伴随英国多中心、开放标签、随机对照试验开展,从医疗保健部门视角进行。
- 效果采用3水平EuroQol 5维度(EQ-5D-3L)测量并计算质量调整生命年(QALY)。
- 呈现增量成本效果比(ICER),代表48周时间范围内每获得一个QALY的额外成本。
- 进行敏感性分析评估分析方法与假设变化对成本效果估计的影响。
主要发现
- TC组平均成本为£4,198,标准治疗组为£2,000。
- TC组平均QALY为0.602,标准治疗组为0.561。
- ICER为£53,948/QALY。
- Bootstrap不确定性分析提示在£20,000阈值下TC具有成本效果的概率为0.07。
- 分层分析提示在控制某些成本后,疾病严重程度较高的患者ICER为£24,639。
关键数值与推荐
- 成本效果阈值参考£20,000/QALY,该阈值下TC具有成本效果的概率为0.07。
- 疾病严重程度较高的患者、在控制部分成本后ICER为£24,639/QALY。
临床怎么用
- TC策略虽有效,但在多数分析中未达成本效果,临床推广需结合支付阈值与患者选择。
- 对疾病严重程度较高的患者、在控制部分成本后ICER可降至£24,639,提示可优先考虑该人群。
- 降低药物价格、减少风湿科就诊频率可能改善TC策略的性价比。
局限性
- 成本效果分析基于48周时间范围,未涵盖更长周期的成本与效果。
- 分析采用医疗保健部门视角,未纳入社会视角的其他成本。
- 分层分析中ICER£24,639依赖于对某些成本进行控制的假设。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Treat-to-target approaches have proved to be effective in rheumatoid arthritis, but have not been studied in psoriatic arthritis (PsA). This study was undertaken to examine the cost-effectiveness of tight control (TC) of inflammation in early PsA compared to standard care. METHODS: Cost-effectiveness analyses were undertaken alongside a UK-based, open-label, multicenter, randomized controlled trial. Taking the perspective of the health care sector, effectiveness was measured using the 3-level EuroQol 5-domain, which allows for the calculation of quality-adjusted life-years (QALYs). Incremental cost-effectiveness ratios (ICERs) are presented, which represent the additional cost per QALY gained over a 48-week time horizon. Sensitivity analyses are presented assessing the impact of variations in the analytical approach and assumptions on the cost-effectiveness estimates. RESULTS: The mean cost and QALYs were higher in the TC group: £4,198 versus £2,000 and 0.602 versus 0.561. These values yielded an ICER of £53,948 per QALY. Bootstrapped uncertainty analysis suggests that the TC has a 0.07 probability of being cost-effective at a £20,000 threshold. Stratified analysis suggests that with certain costs being controlled, an ICER of £24,639 can be calculated for patients with a higher degree of disease severity. CONCLUSION: A tight control strategy to treat PsA is an effective intervention in the treatment pathway; however, this study does not find tight control to be cost-effective in most analyses. Lower drug prices, targeting polyarthritis patients, or reducing the frequency of rheumatology visits may improve value for money metrics in future studies.
引用
- O'Dwyer JL, Meads DM, Hulme CT, et al. Cost-Effectiveness of Tight Control of Inflammation in Early Psoriatic Arthritis: Economic Analysis of a Multicenter Randomized Controlled Trial. Arthritis Care Res (Hoboken). 2018. PMID: 28544822. doi:10.1002/acr.23293
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。